E75.09

Clinical Causes: Inherited genetic mutations that lead to enzyme deficiencies essential for breaking down GM2 gangliosides. Autosomal recessive inheritance pattern: both parents typically carry a copy of the mutated gene. Deficiency in enzymes such as hexosaminidase A, which is crucial for degrading GM2 gangliosides.

Key Symptoms: Progressive loss of motor skills and muscle weakness. Developmental delays in children. Loss of hearing and vision. Seizures and episodic neurological symptoms. Ataxia, which affects balance and coordination. Behavioral changes, confusion, or cognitive decline. In adult forms, symptoms may progress more slowly and can include psychiatric issues and movement disorders.

Diagnosis Path: Diagnosis typically involves a combination of clinical evaluation, family history assessment, and laboratory tests. Key diagnostic steps include: - Enzyme activity testing to measure levels of hexosaminidase A. - Genetic testing to identify mutations in genes associated with GM2 gangliosidosis. - Neuroimaging studies such as MRI to observe brain changes. - Analysis of skin, blood, or cerebrospinal fluid samples for accumulated gangliosides. Early diagnosis is crucial for managing symptoms and planning care, although currently, there is no cure for the condition.

Treatment Protocols: Management of Other GM2 gangliosidosis focuses on alleviating symptoms and improving quality of life. Approaches include: - Supportive therapies such as physical, occupational, and speech therapy. - Medications to control seizures and manage neurological symptoms. - Nutritional support and assistance with daily activities. - Experimental treatments like enzyme replacement therapy are under research but are not yet widely available. - Regular monitoring and a multidisciplinary care team to address the evolving needs of individuals with the condition.